Incretin-based therapy and pancreatic beta cells.

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Type 2 diabetes (T2D) is a progressive global health issue driven by pancreatic beta cell dysfunction and insulin resistance.
• Current glucose-lowering therapies often fail to achieve target goals for many T2D patients.
• Pancreatic beta cell dysfunction is a critical factor in T2D development.

Purpose of the Study:

• To review the current understanding of pancreatic beta cell incretin system dysfunction in T2D.
• To summarize evidence on the impact of incretin-based therapies on beta cell function and mass.
• To highlight the potential of GLP1RA and DPP4I in T2D management.

Main Methods:

• Literature review of current research on T2D pathogenesis and incretin-based therapies.
• Analysis of preclinical (animal) and clinical (human) studies.
• Focus on glucagon-like peptide-1 receptor agonists (GLP1RA) and dipeptidyl peptidase-4 inhibitors (DPP4I).

Main Results:

• Incretin-based therapies demonstrate significant benefits for beta cell function and mass in animal models.
• In human studies, these therapies are effective glucose-lowering agents.
• Evidence suggests a positive impact of incretin-based treatments on the incretin hormone system.

Conclusions:

• Incretin-based therapies offer a promising approach for T2D management by targeting the incretin system.
• While effective for glucose control, long-term effects on beta cell function, mass, and safety require further investigation in humans.
• Understanding incretin system dysfunction is key to developing improved T2D treatments.